Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough.

Chronic cough Clinically meaningful change Cough monitoring Cough severity Objective cough frequency Patient-reported outcomes

Journal

Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875

Informations de publication

Date de publication:
12 2022
Historique:
received: 08 09 2022
accepted: 19 10 2022
pubmed: 9 11 2022
medline: 23 11 2022
entrez: 8 11 2022
Statut: ppublish

Résumé

Objective cough frequency is used to assess efficacy of chronic cough (CC) treatments. The objective of this study was to explore the relationship between objective cough frequency and cough-specific patient-reported outcomes (PROs) and estimate a clinically meaningful change threshold (MCT) for objective cough frequency. Data collected in a phase 2b study in participants with refractory or unexplained CC were used to investigate the relationship between 24-h cough frequency (measured using an ambulatory cough monitor) and cough-specific PROs (i.e., cough severity visual analog scale, cough severity diary, Leicester Cough Questionnaire). Convergent validity was assessed using Spearman ρ. An MCT for 24-h cough frequency was estimated using the patient global impression of change (PGIC) scale as an anchor. Correlations between 24-h cough frequency and cough-specific PROs at baseline, Week 4, and Week 12 were significant (P < 0.0001) but low to moderate in strength (ρ = 0.30-0.58). Participants categorized as very much improved/much improved (i.e., PGIC of 1 or 2) or minimally improved (i.e., PGIC of 3) had mean 24-h cough frequency reductions of 55% and 30%, respectively. Receiver operating characteristic curve analysis suggested that a 24-h cough frequency reduction of 38% optimizes sensitivity and specificity for predicting a PGIC score of 1-3. Objective 24-h cough frequency is significantly associated with cough-specific PROs, but cough frequency and PROs most likely capture distinct aspects of CC. A ≥ 30% reduction in 24-h cough frequency is a reasonable MCT to define treatment response in CC clinical trials.

Identifiants

pubmed: 36348054
doi: 10.1007/s00408-022-00587-2
pii: 10.1007/s00408-022-00587-2
pmc: PMC9675653
doi:

Banques de données

ClinicalTrials.gov
['NCT02612610']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

717-724

Informations de copyright

© 2022. The Author(s).

Références

Lancet Respir Med. 2017 Oct;5(10):806-815
pubmed: 28923239
Eur Respir J. 2021 Aug 12;58(2):
pubmed: 33875494
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1711-1714
pubmed: 31002958
Eur Respir J. 2008 Jul;32(1):175-9
pubmed: 18287128
Lung. 2021 Apr;199(2):121-129
pubmed: 33825965
Lung. 2015 Jun;193(3):401-8
pubmed: 25787221
Int J Clin Pharmacol Ther. 2017 Sep;55(9):712-719
pubmed: 28679467
Curr Med Res Opin. 2020 Jan;36(1):139-150
pubmed: 31558053
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31949115
Thorax. 2009 May;64(5):393-8
pubmed: 19131447
Respirology. 2011 Feb;16(2):314-20
pubmed: 21054670
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620915155
pubmed: 32345170
Lancet Respir Med. 2020 Aug;8(8):775-785
pubmed: 32109425
Chest. 2018 Jan;153(1):196-209
pubmed: 29080708
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743
pubmed: 34697975
Respir Med. 2013 Mar;107(3):408-12
pubmed: 23261310
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1715-1723
pubmed: 30928483
Am J Respir Crit Care Med. 2013 May 1;187(9):943-9
pubmed: 23471467
J Allergy Clin Immunol Pract. 2020 May;8(5):1645-1657.e7
pubmed: 32059869
Thorax. 2003 Apr;58(4):339-43
pubmed: 12668799
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31515408
Eur Respir J. 2013 Feb;41(2):277-84
pubmed: 22743673
Chest. 2011 Mar;139(3):569-575
pubmed: 20864619
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1255-1263
pubmed: 28650204
Handb Exp Pharmacol. 2009;(187):311-20
pubmed: 18825348
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
BMJ Open. 2019 Jun 11;9(6):e030945
pubmed: 31189685
Chest. 2016 Jun;149(6):1460-6
pubmed: 26973014
BMC Pulm Med. 2017 Nov 21;17(1):146
pubmed: 29162060
J Allergy Clin Immunol. 2014 Jul;134(1):56-62
pubmed: 24666696
Chest. 2020 Jan;157(1):111-118
pubmed: 31421110

Auteurs

Jonathan Schelfhout (J)

Merck & Co., Inc., Rahway, NJ, USA.

Allison Martin Nguyen (AM)

Merck & Co., Inc., Rahway, NJ, USA.

Surinder S Birring (SS)

Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Elizabeth D Bacci (ED)

Evidera, Seattle, WA, USA.

Margaret Vernon (M)

Evidera, Bethesda, MD, USA.

David R Muccino (DR)

Merck & Co., Inc., Rahway, NJ, USA.

Carmen La Rosa (C)

Merck & Co., Inc., Rahway, NJ, USA.

Jaclyn A Smith (JA)

Division of Infection, Immunity and Respiratory Medicine, 2nd Floor Education and Research Centre, University of Manchester and Manchester University NHS Foundation Trust, Southmoor Rd, Wythenshawe, Manchester, M23 9LT, UK. Jacky.Smith@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH